Loading
TransMedics Group, Inc. Stock: price and insider trades · United States
1 insider bought €94k of shares over the last 90 days, the latest by Weill David, filed 14 Sept 2026.
TransMedics Group, Inc.: what insiders have been doing
Every trade that managers of TransMedics Group, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Over the twelve months to 22 October 2026, 28 filings were filed, from 11 insiders.
Purchases and sales both appear in the filings: 2 purchases (2 insiders, €955k) and 11 sales (6 insiders, €3.6M). Sales outweigh purchases by €2.6M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The buyers include 1 senior executive and 1 chief executive. One trade stands out by size: a purchase of €861k from Hassanein Waleed H, disclosed on 18 November 2025.
With 28 filings in twelve months, the company is more active than the median of 24 filings across the 3,171 companies we follow on the same exchange. Over the whole record (from 2019), the tally stands at 11 purchases and 420 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 605.5 m USD and net income at 190.3 m USD.
The most recent open-market purchase was published on 14 September 2026, 39 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
740
Thresholds
n/a
Buy Volume
€6M
11 ops. · all time
Sell Volume
€160M
420 ops. · all time
Who traded when
BuySaleEdward M. Basile6 sales
Khayal Tamer I5 sales
David Weill1 buy3 sales
Gerardo Hernandez4 sales
Waleed H. Hassanein4 buys
Anil P. Ranganath3 sales
+2 other insiders
Since the insiders bought
- -17.8%Entry US$88.09 · Close 16 Oct 2026 US$72.39
- +0.3%Entry US$133.47 · Close at T+90 US$133.82
- +174.0%Entry US$22.54 · Close at T+365 US$61.76
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate TransMedics Group, Inc. Buy (bullish), based on 11 analysts. Average price target: US$98.73.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 6,253 of 26,246 companies
64.8
score / 100
Value55
Quality75
FCF yld5.2%
Earn yld7.4%
EV/EBITDA20.9x
ROE36%
Gross mgn60%
Net mgn31%
Debt/EBITDA3.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$74.75
Analyst consensus
11 analystsBuy
US$65.00Target US$98.73(+32%)US$125.00
Income statement
RevenueUS$605.5M
Gross profitUS$362.8M60% margin
EBITDAUS$148.5M25% margin
Net incomeUS$190.3M22.7% margin
Valuation
PER (trailing)19.4x
PER (forward)33.2x
P/Book5.0x
Beta1.93
Balance sheet & cash
Market capUS$2.6B
Total debtUS$519.3M
Free Cash FlowUS$133.6M
Debt / Equity167%
Profitability & ownership
ROE36.3%
ROA4.3%
% insiders3.6%
% institutions103.0%
Last declaration on 14 September 2026
Declarations740 total
1,336 shares@ US$81.630.0043% mcap6.8% of flowCommon StockSEC:0001193125-26-390650:0
Canonical exit: 10 Dec 2026 (T+90)
18,000 shares0Common StockSEC:0001193125-26-354202:0
11,727 shares0Common StockSEC:0001193125-26-303713:0
49,669 shares0Common StockSEC:0001193125-26-303704:0
17,246 shares0Common StockSEC:0001193125-26-303710:0
9,624 shares@ US$75.06270.029% mcap100.0% of flowCommonSEC144:0001950047-26-006158
2,922 shares0Common StockSEC:0001193125-26-236908:0
15,409 shares0Common StockSEC:0001193125-26-235072:0
3,571 shares@ US$146.8210.9% of flowCommon StockSEC:0001193125-26-097051:1
1,193 shares@ US$149.6246.4% of flowCommon StockSEC:0001193125-26-097058:0
3,571 shares@ US$14.203.6% of flowCommon StockSEC:0001193125-26-097051:0
1,324 shares@ US$77.125.8% of flowCommon StockSEC:0001193125-26-092241:1
1,324 shares@ US$147.2111.1% of flowCommon StockSEC:0001193125-26-092241:2
5,912 shares@ US$69.8423.5% of flowCommon StockSEC:0001193125-26-092241:3
5,912 shares@ US$147.2149.5% of flowCommon StockSEC:0001193125-26-092241:4
2,966 shares@ US$139.1211.5% of flowCommon StockSEC:0001193125-26-092182:1
375 shares@ US$139.1228.7% of flowCommon StockSEC:0001193125-26-092241:0
864 shares@ US$139.1219.7% of flowCommon StockSEC:0001193125-26-092183:0
984 shares@ US$135.3011.8% of flowCommon StockSEC:0001193125-26-092182:0
11,082 shares0Common StockSEC:0001193125-26-061341:0
5,000 shares@ US$138.6414.4% of flowCommon StockSEC:0001193125-25-309751:1
5,000 shares@ US$14.205.0% of flowCommon StockSEC:0001193125-25-309751:0
920 shares@ US$139.6271.3% of flowCommon StockSEC:0001193125-25-309750:0
3,000 shares@ US$145.2220.3% of flowCommon StockSEC:0001193125-25-300644:1
3,000 shares@ US$93.8847.2% of flowCommon StockSEC:0001193125-25-300644:0
25 of 740 declarations
About TransMedics Group, Inc.
TransMedics Group, Inc. is a U.S.-listed medical technology company quoted on the Nasdaq in the United States under the ticker TMDX. The company operates in a highly specialized healthcare niche focused on organ transplantation. It was founded to address the persistent shortage of transplantable organs and to improve how donor organs are preserved, assessed, and transported before implantation. TransMedics’ historic headquarters are in Andover, Massachusetts, and in 2026 the company announced a new global headquarters lease in Somerville, Massachusetts, with plans to consolidate corporate, R&D, and advanced manufacturing functions on an integrated campus.
The company’s core business is built around its Organ Care System, or OCS, an ex vivo organ perfusion platform designed to keep organs in a more physiologic state than traditional static cold storage. Its principal commercial focus is on heart, lung, and liver transplantation, combined with a broader set of services tied to transplant logistics and case execution. This means TransMedics is not simply a device vendor; it is increasingly operating as a platform business that monetizes both products and services. That model can support stronger customer stickiness and operating leverage over time, although it also leaves the company exposed to regulatory scrutiny, clinical adoption risk, and reimbursement dynamics typical of medtech businesses.
Read moreShow less
From a competitive standpoint, TransMedics occupies a differentiated position in a market with high technical barriers. The value proposition extends beyond organ preservation hardware to an end-to-end transplant solution that includes viability assessment and transport coordination. In practice, this has helped the company build its National OCS Program in the United States, which remains the main commercial engine. The strategic logic is that if TransMedics can own more of the transplant workflow, it can deepen its moat versus conventional preservation methods and fragmentary competitors. The company is also signaling an international growth ambition, particularly in Europe, where transplant logistics remains less standardized and more fragmented.
Recent developments have been meaningful for the investment case. In its February 2026 full-year results, TransMedics reported strong revenue growth for 2025 and a substantial increase in U.S. OCS cases, underscoring continued commercial traction. Management also highlighted FDA approval for the OCS ENHANCE Heart and DENOVO Lung trials, an important milestone for future clinical evidence generation and potential label expansion. In parallel, the company announced a strategic investment aimed at creating the first dedicated European transplant logistics network through PAD Aviation, and it disclosed a collaboration with Mercedes-Benz to launch a dedicated ground transportation network for organ transplantation in Italy. Overall, TransMedics is a fast-scaling U.S. medtech company with a differentiated transplant platform, a strong domestic base, and clear ambitions to expand its operational footprint internationally.
